Focus Stocks
Sanofi-Aventis Close to Resistance
Published on Wednesday, 08 February 2012 08:00 Written by TradersHuddle Wire
New York, February 8th (TradersHuddle.com) - Shares of Sanofi-Aventis (NYSE:SNY) are trading very close to calculated resistance at $37.58 with the current price action closing at just $37.54 placing the stock near levels that make it difficult to buy.
Sanofi-Aventis (NYSE:SNY) is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines. The Company develops cardiovascular, thrombosis, metabolic disorder, central nervous system, internal medicine and oncology drugs, and vaccines.
Sanofi-Aventis' current stock range is defined by current calculated support defined at $35.09 and by the resistance level at $37.58, the stock is clearly over-extended from support, making it difficult to establishing new long positions at this level.
Traders don't have a clear entry point for Sanofi-Aventis , as the stock is well above support, however, as the stock pulls back towards $35.09 it will definitely provide a reference point to establish a trade. On the other hand if the stock decides to break above resistance level at $37.58 then traders will get an opportunity to enter Sanofi-Aventis stock by establishing a position as the stock moves to a higher range.
Related Articles
- Europe: More Is Needed
- Is Sanofi-Aventis Resistance Ahead?
- Sanofi-Aventis Is Dipping Below Support
- New Ratings: NVS, SNY, CYS
- Sanofi-Aventis Is Close to its 200 Day Moving Average
- Trading Idea: Is Sanofi-Aventis close to Support?
- Reference Points for Sanofi-Aventis
- Genzyme Announces Regulatory Approvals of Expanded Waterford, Ireland Manufacturing Plant
- Sanofi iBGStar® Blood Glucose Monitoring System Now Available in the U.S.
- Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
Related Partner Headlines
- Sanofi (SNY): Today's Featured Health Care Loser - TheStreet.com
- Sanofi Stock To Go Ex-dividend Monday (SNY) - TheStreet.com
- Sanofi Q1 Net Profit Jumps 50% - Benzinga
- Talon: Assessing Marqibo's FDA Odds - TheStreet.com
- Sanofi Announces FDA Approval of Sklice® Lotion for the Treatment of Head Lice - Benzinga
- Sanofi (SNY): Today's Featured Health Care Loser - TheStreet.com
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Coming Week: Top Nine Earnings on Deck - TheStreet.com -
Something's Not Right in the Video-Game Space - TheStreet.com -
For Ambitious Students, Entrepreneurship Can Be a Big Win - TheStreet.com -
Stock Futures Rise on Eurobond Talk - TheStreet.com -
You Can Let Your Guard Down: Ask Noah - TheStreet.com -
Apple Strengthens Its Supply Chain - TheStreet.com -
NYSE Is Winning the IPO Listing War - TheStreet.com -
Toyota Is Back as May Sales Continue Auto Industry Recovery - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis -
SunOpta Enters Into Agreement to Divest Its Canadian Based Natural Health Products Business -
PC Connection, Inc. (PCCC) To Present at The SeeThruEquity First Annual Small Cap Investor Conference on Tuesday, June 5, 2012 -
Aeroflex Announces Amendment to Credit Agreement -
Alliance Data to Participate at Upcoming Investor Conferences -
PCA3 Test Featured at American Urological Association Meeting -
MOCON Announces Quarterly Dividend -
Government of Rwanda Introduces Merck's ROTATEQ® (Rotavirus Vaccine, Live, Oral, Pentavalent) to Help Protect Children Against Rotavirus









